Skip to content
Current & ScaleNiagara River · A cross-border field guide

Lake Erie / Niagara / Lake Ontario
New York & Ontario

Explore the field guide

Rules & planning / Field entry 33

MDR1 Medication Cautions for Trail Dogs

How the MDR1 mutation changes drug handling in dogs, which molecules to avoid, and what owners should check before anaesthesia or heartworm prevention.

·

A veterinary examination table in daylight, a cheek swab tube and a printed MDR1 test result lying beside a stethoscope, close overhead framing on the paperwork and the dog's collar tag at the edge of the frame
Illustration / A veterinary examination table in daylight, a cheek swab tube and a printed MDR1 test result lying beside a stethoscope, close overhead framing on the paperwork and the dog's collar tag at the edge of the frame

The MDR1 mutation removes part of a dog's normal blood-brain barrier pump, so certain drugs reach the brain at far higher concentrations than in a dog without the mutation. That single change explains why a standard dose of ivermectin or a routine anaesthetic protocol can cause tremors, ataxia, blindness or coma in affected Collies, Australian Shepherds and related breeds. Owners who know their dog's MDR1 status can hand a veterinarian a concrete list of molecules to avoid, which is the practical core of MDR1 sensitivity management for these breeds.

How does the MDR1 mutation change a dog's handling of some drugs?

The MDR1 gene codes for P-glycoprotein, a transport protein that sits in the cells lining the small intestine, the bile canaliculi, the renal tubules and the endothelial cells of the blood-brain barrier. Its job is to pump a broad range of foreign molecules back out of those tissues. In the brain capillaries, P-glycoprotein acts as a gatekeeper: it recognises substrates that have crossed from blood into endothelial cells and returns them to the bloodstream.

A mutation in the MDR1 gene, most often a four base pair deletion, produces a truncated, non-functional protein. Without working P-glycoprotein at the blood-brain barrier, substrates that would normally be excluded accumulate in the central nervous system. The plasma dose may be perfectly ordinary; the brain concentration is not. This is why toxicity in affected dogs is a function of genotype rather than of overdose, and why two dogs of the same weight given the same tablet can respond in completely different ways.

The mutation is inherited as an autosomal recessive trait. A dog with two copies, often written MDR1 -/- or affected, has no functional pump. A carrier with one copy, MDR1 +/-, generally tolerates standard doses but can pass the mutation to offspring. A clear dog, MDR1 +/+, has two normal copies. Prevalence is highest in Collies, Long-haired Whippets, Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs and German Shepherd lines, and it also appears in mixed-breed dogs with those ancestries. A dog that looks like a generic shepherd mix can still be affected, so appearance is not a substitute for a test.

Testing is done from a cheek swab or a blood sample submitted to a veterinary genetics laboratory. Results are reported as clear, carrier or affected. Puppies can be tested at any age because the genotype is present from conception; there is no need to wait for maturity. Breeders use the result to plan pairings, and owners use it to build a drug list with their veterinarian before any treatment is needed.

Which molecules belong on the avoid list?

The toxic class is the macrocyclic lactones, a family of antiparasitic compounds that includes ivermectin, milbemycin oxime, moxidectin, selamectin, doramectin and eprinomectin. These are the molecules that interact most directly with the defective pump. Risk depends on dose and route: the low doses used in monthly heartworm preventives are usually tolerated by affected dogs, while the high doses used to treat mange, or any injectable formulation given at mange-level dosing, are the classic trigger of severe neurological signs.

Beyond the macrocyclic lactones, several other drugs are recognised substrates of P-glycoprotein and warrant caution in affected dogs. These include loperamide, the common over-the-counter antidiarrheal, which can produce central nervous system depression at ordinary label doses. Certain chemotherapy agents, among them vincristine, vinblastine, doxorubicin and paclitaxel, are also substrates and require dose adjustment or substitution. Some opioid analgesics and certain antiemetics used in veterinary practice fall into the same category, which is why the anaesthesia plan matters as much as the parasite plan.

Signs of toxicity are neurological and can progress quickly: tremors, hypersalivation, vomiting, unsteady gait, dilated pupils, apparent blindness, disorientation, recumbency, seizures and coma. Onset is often within hours of exposure. There is no at-home antidote. An affected dog showing these signs needs immediate veterinary care, and the veterinarian may use supportive therapy, seizure control and, in severe cases, intravenous lipid emulsion therapy. Recovery is possible, but it depends on how fast treatment starts and how much drug reached the brain.

What should an owner check before anaesthesia or a preventive treatment?

Before any procedure or prescription, three items belong in the conversation. First, the dog's MDR1 test result, in writing, with the laboratory name and the date. Second, the complete list of drugs the veterinarian plans to use, including premedication, induction agent, maintenance anaesthetic, any perioperative analgesic and any antiparasitic given the same day. Third, the dose and route for each of those drugs, because a molecule that is safe at a preventive dose may not be safe at a therapeutic one.

For anaesthesia, the concern is not only the anaesthetic itself but the whole protocol. Premedication opioids, some sedatives and certain antiemetics given during recovery can all be P-glycoprotein substrates. A veterinarian who knows the dog is affected can choose alternatives, reduce doses where appropriate and extend monitoring through the recovery period rather than discharging the dog as soon as it stands.

For heartworm prevention, the question is which product and at what dose. Monthly preventives containing low-dose ivermectin or milbemycin are widely used in affected dogs under veterinary supervision, but the decision belongs to the veterinarian who has the test result and the product label in front of them. Injectable or high-dose formulations used for other parasites are a different matter and should be avoided unless a veterinarian with knowledge of the genotype explicitly directs otherwise.

Managing the mutation day to day

A diagnosis is not a lifetime of restrictions; it is a short list of rules. Keep the MDR1 result with the dog's vaccination record and take a copy to every new clinic, boarding facility or emergency hospital. Tell the staff at intake, before any drug is offered, that the dog is affected. Ask about every new medication, including over-the-counter products, because loperamide and some other human preparations are sold without a prescription and are easy to give without thinking.

Household and travel planning follow the same logic. Boarding kennels and sitters should have the written drug list, and any deworming or flea product applied on site should be checked against it. If a dog is travelling, the same list goes in the travel folder. Owners of affected dogs often find that a single page, updated once a year with the veterinarian, prevents most of the avoidable exposures.

What owners of Collies and related breeds should take away

The MDR1 mutation is common enough in Collies, Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs and their crosses that testing is a reasonable first step for any dog with that ancestry. A swab result turns an abstract risk into a specific plan: which molecules to avoid, which doses are acceptable, and what to do if a mistake happens. The information is stable, the test is inexpensive relative to an emergency visit, and the plan is portable across clinics, kennels and borders. Owners who hold that plan are in a position to protect their dog at the exact moment it matters, which is when a syringe or a tablet is already in someone's hand.

Collie eye anomaly is diagnosed by an ophthalmoscopic eye exam, usually between six and eight weeks of age, and graded by how much of the choroid failed to develop. A DNA test for the NHEJ1 mutation on chromosome 37 identifies carriers, though the visible grade, not the genotype alone, determines severity. Breeds and crosses screened include collies, Shetland sheepdogs, Australian shepherds, and their mixes. A breeding plan pairs an affected or carrier dog with a genetically clear mate rather than removing it from the program, which is part of living with a screened collie. The Current & Scale field desk keeps a dated entry on this at living with a screened collie.